ADMA Biologics, Inc. (ADMA) Q1 2022 Earnings Results

ADMA Biologics Misses on EPS, Stock Down 11.18%

ADMA Biologics reported a loss that was worse than expected, leading to a significant drop in stock price. The lack of revenue data and guidance contributed to investor uncertainty. The stock's decline reflects concerns about the company's ability to navigate current challenges and improve performance in the future.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.13	N/A	-62.50%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced in the quarter. They emphasized a commitment to addressing operational hurdles.

Management did not provide specific insights into revenue performance.

The company is focused on navigating current market challenges.

ADMA Biologics Misses on EPS, Stock Down 11.18%

Key numbers

Management commentary

ADMA Biologics, Inc.

More earnings this week

ADMA Biologics Misses on EPS, Stock Down 11.18%

Key numbers

Management commentary